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STUDY QUESTION: To evaluate the implementation of the coding systems in medically assisted reproduction (MAR) centres in the
European Union (EU).
SUMMARY ANSWER: Our data show that a significant number of MAR centres use the Single European Code (SEC), but it also shows
certain limitations to the coding.
WHAT IS KNOWN ALREADY: Traceability and identification of tissue and cells used for clinical application are extremely important as
it is one of the key aspects of quality and safety both for the donors and the recipients. Patients as well as tissues and cells move across
the European continent and far beyond, hence a uniform coding system was very much needed. The coding of tissues and cells from hu-
man origin was already embedded in the EU directives 2004/23/EC. The use of the Single European Code (SEC) on tissues and cells was
enforced in 2017 for tissues and cells distributed within the EU or exported from the EU. The SEC ensures standardization within the EU,
allowing the integration of the two existing codes (ISBT-128 and Eurocode) within the SEC structure. Likewise, in the MAR field, the SEC
was launched in order to ensure the traceability of reproductive tissues and cells. Gametes and embryos from partner donation as well as
reproductive cells and tissues of allogeneic donation were excluded from the SEC as long as they remain in the centre of origin.
STUDY DESIGN, SIZE, DURATION: A cross-sectional survey aimed to gain insight into the use of SEC by MAR centres was con-
ducted between 5 November and 15 December 2018.
PARTICIPANTS/MATERIALS, SETTING, METHODS: The online survey was distributed among the ESHRE members.
MAIN RESULTS AND THE ROLE OF CHANCE: The survey results highlight the strengths and weaknesses in the practical use of the
SEC. The data from the survey showed that the SEC code is something that is known in the MAR field. Our data showed that over half of
the respondents were using the SEC in their centre. On the other hand, there is also criticism about the use of SEC in MAR, especially
that the added value for traceability and identification in ART is found to be rather limited.
LIMITATIONS, REASONS FOR CAUTION: The survey response rate was rather low (4.84%). The view of the use of SEC discussed
in this paper still provides insight into the use of the SEC in several MAR centres.
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WIDER IMPLICATIONS OF THE FINDINGS: The survey highlights some knowledge gaps concerning coding. This information can be
used to develop tools to increase knowledge of the SEC.
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no conflict of interest.
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Introduction
An effective traceability system represents a crucial aspect in medically
assisted reproduction (MAR) treatments. In fact, donor selection, col-
lection from the donor, processing, storage and transport of tissues
and cells involve many complex steps that impact on the quality and
safety of tissues and cells used for human application. For this reason,
all steps and procedures to which tissues or cells are subjected need
to be identified. Their location and employed equipment and materials
need to be recorded before reaching the recipient. The chain of trace-
ability in MAR includes not only the link between donors and recipi-
ents but also the follow-up of pregnancies and data on children’s
health. Human errors, equipment failures and use of inadequate writ-
ten procedures can increase safety and health risks not only to recipi-
ents but also to offspring. When incidents happen, the ability to track
and trace back every step in the process chain helps to find the root
cause. In turn, corrective measures can be set up and possible risks in
other processes detected and prevented.
The system of traceability is based on a coding system that prefera-
bly consists of a globally unique identification code for all donated bio-
logical products. In general, gametes and embryos are currently
labelled and coded, hence identified, by local or national traceability
systems. Although these systems work perfectly well inside a MAR es-
tablishment, many people travel abroad to access fertility treatments
and this leads to an increase in the cross-border movement not only
of patients, but also of tissues and cells (Shenfield et al., 2011). The
need for a universal code aimed at connecting the internal traceability
chains of two or more MAR centres is essential. A common traceabil-
ity language, that is understood and readable all over Europe, should
facilitate tracing the tissues and cells from donors to recipients and
vice versa.
In the European Union (EU), there are three types of coding sys-
tems that can be used: (i) ISBT-128, (ii) Eurocode and (iii) Single
European Code (SEC) for tissues and cells.
The International Council for Commonality in Blood Banking
Automation, an international non-profit non-governmental organization
in official relations with the World Health Organization, manages the
ISBT-128, which is the most widely used information standard for the
coding and labelling of medical products of human origin. It is used in
77 countries across six continents and is endorsed by 21 scientific and
professional organizations (Cabana, 2018; Rice, 2018). Recently, a new
terminology was developed for the description of MAR products and
it is compatible with the ISBT-128 coding system (Ashford et al.,
2019).
Eurocode International Blood Labelling Systems e.V. (Eurocode
IBLS) is a non-profit organization under German law founded in 1998.
Eurocode IBLS manages the coding Eurocode that is established today
as a coding system for products of human origin mainly in Germany. It
incorporates current International Organization for Standardization
(ISO) standards, providing worldwide unique identifiers for labelling
blood products, cells and tissues (Knels et al., 2017).
In 2015, the European Commission Directive (EU) 2015/565
amended Directive 2006/86/EC regarding certain technical require-
ments for the coding of human tissues and cells (European
Commission, 2006) (European Commission, 2015) . The directive in-
troduced the obligation for tissue establishments to use a SEC on tis-
sues and cells distributed for clinical application in the EU or exported
from the EU. The SEC ensures the standardization within the EU,
allowing the use of ISBT-128 or Eurocode integrated within the SEC
coding structure (Caramia et al., 2017).
The SEC should be applied to all tissues and cells used for human
application but with some exceptions including cases of partner dona-
tion of reproductive cells or when donated tissues and cells remain in
the same centre. Other exceptions are when reproductive cells are
imported from non-EU countries into the EU in case of an emergency
authorized directly by the Competent Authorities, or when tissues and
cells that are imported from non-EU countries into the EU remain
within the same centre from importation to application, providing that
WHAT DOES THIS MEAN FOR PATIENTS?
The paper describes how coding of samples is applied in Europe, to make sure that there is traceability when reproductive cells for non-
partner donations are transported between centres. There are several recommendations and legislation on how this could be done (sev-
eral codes), and we asked centres using medically assisted reproduction which coding system they use and which problems they encounter
using the codes.
The collected information could help to further improve and standardize labelling of samples in the IVF laboratory that are used in non-
partner donation. It is not directly relevant for patients, however, indirectly it is of interest as patients who are receiving donated reproduc-
tive material that has been transported can be reassured that the traceability chain is complete, from centre of origin to the centre where
they receive the treatment.




























































the centre is a tissue establishment that is authorized, designed,
accredited or licensed to carry out importing activities.
The SEC is a unique identifier consisting of two elements: a dona-
tion identification sequence and a product identification sequence
(Fig. 1). The donation identification sequence indicates the origin of
tissues or cells, mainly because every donor could potentially do-
nate tissues and cells on several occasions (e.g. gamete donation).
This sequence is made up of the tissue establishment code, which
is composed of the ISO country code in combination with the tis-
sue establishment number allocated in the EU Tissue Establishment
Compendium (2020). This represents a register of all tissue estab-
lishments that are authorized and licensed by Competent
Authorities of the EU member states (accessible through https://
webgate.ec.europa.eu/eucoding/reports/te/index.xhtml). Each tis-
sue establishment should assign a unique number for the donation,
which is 13 characters in length and based on the donation identifi-
cation system currently in use in their country. In fact, the donation
number may be locally defined or be aligned with national or inter-
national standards. The second part of the SEC is a product identifi-
cation sequence that classifies the type of tissue or cells. It consists
of the assigned product code, a split number (if applicable) and the
expiry date of the product. The product code includes an identifier
of the coding system used. Three systems are approved for use in
the SEC: ISBT-128, Eurocode and the European Union Tissues
Code (EUTC). Then, the product coding system identifier is ‘A’ for
ISBT-128 or ‘B’ for Eurocode or ‘E’ for EUTC, followed by the ap-
propriate product number corresponding to the tissue/cell type,
allowing tissue establishments to use one of three product coding
systems (ISBT-128, Eurocode, EUTC). The split number is used to
identify each product where the donation identification sequence
and product code are the same for multiple products, such as mul-
tiple cryopreservation devices of oocytes from the same donor.
The expiration date of the product is expressed as an eight-digit
number using ISO 8601 in International format (YYYYMMDD).
Depending on local legislation, the expiry date can be addressed in
the SEC. In the case where there is no expiry date described by lo-
cal legislation, this date should be set to 00000000.
The SEC has to be printed in eye-readable format, it should be
printed on the label bonded to the tissue or cell packaging, and it has
to be recorded in the product-related accompanying documents.
Where there is insufficient space for its inclusion on the label, it must
appear in accompanying documentation, which is packed together
with the product. An example of the SEC is given in Fig. 2.
Application of the SEC by EU tissue establishments has been man-
datory since 29 April 2017. However, many establishments have not
implemented the coding systems yet. This cross-sectional study was
conducted to evaluate the implementation of the coding systems in
the EU in MAR centres.
Materials and methods
A cross-sectional study was conducted using an online survey, which
focused on the use of coding systems in MAR. The questionnaire was
set up by ESHRE and distributed amongst its members.
The survey was set up in SurveyMonkey and included 18 questions
organized in two sections: the first focused on the participants’ back-
ground and the second on the use of the coding system in MAR.
Participants were asked about denominations and setting of the
MAR centre (private or public), country and city of work, and profes-
sional career (laboratory director, medical doctor, laboratory techni-
cian, embryologist, quality manager, nurse or other).
The survey was open between 5 November and 15 December
2018. Multiple recruitment strategies were used: the study was adver-
tised via two emails, a first specific e-mail to European ESHRE mem-
bers (n¼ 3752) and a second email to all ESHRE members using a
filter for the European continent (n¼ 5124) and was accessible via the
ESHRE social media.
Figure 1. Explanation of the structure of the Single European Code. ISO, International Organization for Standardization; EUTC,
European Union Tissues Code.




































The survey was sent to 5124 ESHRE members from 114 different
countries. A total of 248 people filled out the survey (participation
rate 4.84%), representing 38 countries. Most of the participants
(96.37%) were from Europe.
The majority of the participants worked in private MAR centres
(n¼ 135/229, 58.95%) while the remainder worked in public centres
(n¼ 94/229, 41.05%). The participants of the survey had different
professional roles, with the majority being laboratory directors
(n¼ 95/231, 41.13%) and embryologists (n¼ 75/231, 32.47%), fol-
lowed by medical doctors (n¼ 40/231, 17.32%). Lab technicians,
nurses, quality managers and other professional roles accounted for
the remaining 9.08% (n¼ 21/231).
The majority of responders was aware of the European Directive on
coding requirements for human tissues and cells (n¼ 192/210, 91.43%)
(Fig. 3a) and used a coding system for traceability in their MAR centres
(n¼ 166/210, 79.05%). Overall, the SEC was used in most centres
(n¼ 98/157, 62.42%) while the use of the Eurocode (n¼ 9/157,
5.73%) and ISBT-128 (n¼ 8/157, 5.10%) represented a very small mi-
nority (Fig. 3b). The category ‘other code’ was answered in 33.76%
(n¼ 53/157) of the cases. The ‘other code’ category was further
explained by 41 participants; 2 replied that they apply a national system,
7 gave no details on the current coding system and 32 reported using an
internal code for identifying gametes and embryos. When details of these
internal codes were described, eight participants reported including the
name of the patients (or other identifier codes for the patients) and/or
date of birth. Seven participants reported using SEC in addition to the in-
ternal coding for specific samples (donation, samples leaving the centre),
and three participants reported being in the process of changing to SEC.
For participants using the SEC code in their practice, a subset of
questions on the application of the SEC was posed. The SEC code is
composed of a 13-digit donation code that is not specified further in
the EU Tissue and Cells Directives (EUTCD). Approximately half of
the respondents (n¼ 30/61, 49.18%) (Fig. 3c), used centre-specific in-
formation to fill this 13-digit donation code. Others could not choose
how to use this donation code as rules were set up by their
Competent Authorities (n¼ 27/61, 44.26%).
Figure 2. Example of Single European Code for reproductive cells and tissues on the basis of EUTC and ISBT128. (a)
Cryopreservation of a mature oocyte. This oocyte is identified as number 5 in a cohort of 10 oocytes. It has been procured in a Belgian tissue estab-
lishment (TE) at Ghent University Hospital that is identified in the Compendium as BE 090014. This TE uses the EUTC to define the product code.
The expiry date for oocyte cryopreservation is 10 years and it was cryopreserved by vitrification on 23 January 2020. Additionally, there is a specific
cycle number that relates the oocyte vitrification to the stimulation of the patient: 09202000145, which is considered the unique donation code in
the SEC. (b) Cryopreservation of a sperm sample (this sample is identified as number 3 in a cohort of 5 from the same ejaculate) in a Swedish TE at
Reproductive Medicine, Gothenburg University Hospital. In the Compendium, the TE number is SE00385. Gametes have no expiry date in Sweden,
so the date is put as 00000000. The unique donation code is made up by a D (as in ‘Donation’) followed by the specific treatment number, thereafter
an L (as in the Swedish word for sequence) followed by an automatically generated sequence number from this clinic: here this was sample number
10 from this clinic. The ISBT-128 code for sperm is then 00R0035.













































For centres that have implemented the SEC in their activities, in half
of the cases the code was used for anonymously donated oocytes
(n¼ 45/99, 45.45%) and sperm (n¼ 50/99, 50.51%). One-third an-
swered that gametes and embryos for partner donation were also
coded using SEC, and 16.16% (n¼ 16/99) of the participants used the
SEC for all types of reproductive cells and tissues. The SEC code was
mostly applied when tissues and cells were transported to other
centres (n¼ 66/101, 65.35%) or upon cryopreservation (n¼ 52/101,
51.49%). Other reasons (n¼ 14/101, 13.86%) for applying the SEC
code were at the start of the MAR treatment cycle, when tissues and
cells were collected or when samples were received from other
centres. The SEC was mostly applied to an accompanying document
(n¼ 88/101, 87.13%), directly on the straw (n¼ 46/101, 45.54%) or
the vial (n¼ 25/101, 24.75%) or the container (n¼ 26/101, 25.74%)
(Fig. 3d).
In answering about the difficulties encountered during the imple-
menting of the code in the laboratory procedures, the majority of res-
ponders declared that the SEC was too long and difficult to put on
devices for cryopreservation. Constructing the code was time-
consuming and given the code length, the readability was found to be
a major weakness.
Although participants reported some difficulties, 67.65% of the
respondents (n¼ 69/102) found the SEC useful for increasing safety and
traceability of cells and tissues during handling and transport between
different clinics. The SEC helped with the sample anonymity as writing
names on the forms accompanying samples can be avoided. Those in fa-
vour of the code found the uniformity across the EU a positive charac-
teristic and probably a first step towards an EU register for donation.
On the contrary, 11.76% of respondents (n¼ 12/102) found the
SEC not useful and found its added value questionable. It would not
aid in the identification and traceability as few centres would really
check it upon receiving samples. Other identifiers, such as the name of
the patient and date of birth or a donor number, were used for track-
ing the samples. According to 20.59% of participants (n¼ 21/102), the
code could be useful in specific cases, for instance for anonymous do-
nated samples.
The EU coding platform was used by 35.45% (n¼ 39/110) of
respondents, mostly to check the license of tissue establishments
where gametes and embryos would be transported to or were origi-
nating from.
The major reason for not having implemented one of the coding
systems as described in the EUTCD was that most clinics already had
an internal coding system for traceability. Some were waiting for their
Competent Authority to give guidance on the implementation of a
coding system or declared that national legislation did not contain a
specific requirement to implement a universal coding system. Others
remarked that they would only use it when samples needed to be
transported, and this situation had not occurred yet.
Figure 3. Detailed answers to four questions of the survey: a) Are you aware of the European directive on coding requirements for human tissues
and cells?; b) What type of coding are you using in your centre?; c) How do you define the 13-digit donations code in the SEC; d) Where do you
apply the code.















































Although the use of a coding system for traceability of reproductive
tissues and cells has been mandatory in the EU since April 2017, not
all centres have implemented the EU coding system. There are some
exceptions for the use of a coding system in MAR: when tissues and
cells are distributed for an immediate clinical application, when do-
nated tissues and cells remain within the same centre, or in the case
of reproductive cells from partner donation: the latter is probably the
main reason for centres not to implement a universal code, but rather
to use an in-house way of identifying gametes and embryos.
Data from this survey showed that the majority of responders found
the use of a code useful. Nevertheless, this survey highlighted many
points of criticism. In order to shed light on the different aspects of
the SEC management, an SWOT (Strengths, Weaknesses,
Opportunities and Threats) analysis was performed (Fig. 4).
The strength of the SEC is its uniform traceability language that can
be understood and read throughout multiple countries. Moreover, the
SEC seems to be easy enough to be generated by a simple Excel sheet
or it can be imbedded into specific software systems. Therefore, the
introduction of the SEC in MAR centres should be easy. The SEC
increases the communication network for tracking reproductive tissues
and cells. Competent Authorities can immediately check and trace the
donors and donations. A unique donor identifier facilitates the trace-
ability when serious adverse events or reactions occur. Hence, the
SEC goes hand in hand with biovigilance.
Currently, the SEC also entails some weaknesses. It is composed of
many digits and a small font size is needed to fit the code on certain
labels. To guarantee the traceability, it should be directly administered
to packaged tissues or cells. Because of the small devices used for cry-
opreserved reproductive cells and tissues, the code on such a label is
difficult to read, and therefore the true value of using the SEC as an
identifier is largely lost. This major weakness may lead to serious
adverse consequences. There is a risk of errors during transcribing
or deciphering such a long code on the containers of reproductive
tissues and cells. In addition, when the code is used on the documen-
tation and a different identifier is used on the straws or vials, this
match has to be consistent throughout the traceability chain. Two
codes to check and control entail a risk for errors, in comparison to
using one code.
Although this survey highlighted critical positive aspects regarding
use of the SEC, some limitations should be considered. The survey re-
sponse rate was rather low (4.84%) and thus the view of the use of
SEC discussed in this paper is incomplete. However, the response rate
is in line with similar surveys distributed to the full ESHRE membership
rather than a specific subgroup (Gameiro et al., 2019). The specific
knowledge about SEC in MAR, and especially the lack of use in the
daily clinical practice in MAR, could have led to colleagues not replying
to the questionnaire. Despite these limitations, we believe that this
survey provides insight into the use of the SEC in several MAR centres.
This paper can raise awareness of SEC and provide information to
centres on the use of SEC.
Figure 4. SWOT analysis of the SEC. SWOT, Strengths, Weaknesses, Opportunities and Threats.






























































..In conclusion, the role of the SEC is to contribute to the safety of
tissue and cells transplant recipients through a system of comprehen-
sive and transparent traceability. Although MAR professionals find the
principle of a universal code for traceability very useful, the use of a
SEC, ISBT-128 or Eurocode is not yet implemented in all MAR
centres. Data from our survey showed that there is a lot of criticism
about the use of SEC in the field of MAR, suggesting that tools to in-
crease knowledge of the code are needed. Some centres use the
code because it is obligatory, but other identifiers are used for true
traceability in the centres.
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